Prognostic value of high-sensitivity cardiac troponin I early after coronary artery bypass graft surgery.
Coronary artery bypass graft
High-sensitivity cardiac troponin I
Left ventricular ejection fraction
Periprocedural myocardial infarction
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
received:
20
05
2022
accepted:
24
09
2022
entrez:
2
11
2022
pubmed:
3
11
2022
medline:
4
11
2022
Statut:
epublish
Résumé
The diagnosis of periprocedural myocardial infarction (PMI) after coronary artery bypass graft (CABG) is based on biochemical markers along with clinical and instrumental findings. However, there is not a clear cutoff value of high-sensitivity cardiac troponin (hs-cTn) to identify PMI. We hypothesized that isolated hs-cTn concentrations in the first 24 h following CABG could predict cardiac adverse events (in-hospital death and PMI) and/or left ventricular ejection fraction (LVEF) decrease. We retrospectively enrolled all consecutive adult patients undergoing CABG, alone or in association with other cardiac surgery procedures, over 1 year. Hs-cTn I concentrations (Access, Beckman Coulter) were serially measured in the post-operative period and analyzed according to post-operative outcomes. 300 patients were enrolled; 71.3% underwent CABG alone, 33.7% for acute coronary syndrome. Most patients showed hs-cTn I values superior to the limit required by the latest guidelines for the diagnosis of PMI. Five patients (1.7%) died, 8% developed a PMI, 10.6% showed a LVEF decrease ≥ 10%. Hs-cTn I concentrations did not significantly differ with respect to death and/or PMI whereas they were associated with LVEF decrease ≥ 10% (p value < 0.005 at any time interval), in particular hs-cTn I values at 9-12 h post-operatively. A hs-cTn I cutoff of 5556 ng/L, a value 281 (for males) and 479 (for females) times higher than the URL, at 9-12 h post-operatively was identified, representing the best balance between sensitivity (55%) and specificity (79%) in predicting LVEF decrease ≥ 10%. Hs-cTn I at 9-12 h post-CABG may be useful to early identify patients at risk for LVEF decrease and to guide early investigation and management of possible post-operative complications.
Sections du résumé
BACKGROUND
BACKGROUND
The diagnosis of periprocedural myocardial infarction (PMI) after coronary artery bypass graft (CABG) is based on biochemical markers along with clinical and instrumental findings. However, there is not a clear cutoff value of high-sensitivity cardiac troponin (hs-cTn) to identify PMI. We hypothesized that isolated hs-cTn concentrations in the first 24 h following CABG could predict cardiac adverse events (in-hospital death and PMI) and/or left ventricular ejection fraction (LVEF) decrease.
METHODS
METHODS
We retrospectively enrolled all consecutive adult patients undergoing CABG, alone or in association with other cardiac surgery procedures, over 1 year. Hs-cTn I concentrations (Access, Beckman Coulter) were serially measured in the post-operative period and analyzed according to post-operative outcomes.
RESULTS
RESULTS
300 patients were enrolled; 71.3% underwent CABG alone, 33.7% for acute coronary syndrome. Most patients showed hs-cTn I values superior to the limit required by the latest guidelines for the diagnosis of PMI. Five patients (1.7%) died, 8% developed a PMI, 10.6% showed a LVEF decrease ≥ 10%. Hs-cTn I concentrations did not significantly differ with respect to death and/or PMI whereas they were associated with LVEF decrease ≥ 10% (p value < 0.005 at any time interval), in particular hs-cTn I values at 9-12 h post-operatively. A hs-cTn I cutoff of 5556 ng/L, a value 281 (for males) and 479 (for females) times higher than the URL, at 9-12 h post-operatively was identified, representing the best balance between sensitivity (55%) and specificity (79%) in predicting LVEF decrease ≥ 10%.
CONCLUSIONS
CONCLUSIONS
Hs-cTn I at 9-12 h post-CABG may be useful to early identify patients at risk for LVEF decrease and to guide early investigation and management of possible post-operative complications.
Identifiants
pubmed: 36319986
doi: 10.1186/s13019-022-02027-x
pii: 10.1186/s13019-022-02027-x
pmc: PMC9628166
doi:
Substances chimiques
Biomarkers
0
Troponin I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280Informations de copyright
© 2022. The Author(s).
Références
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5
pubmed: 22378855
Eur Heart J Acute Cardiovasc Care. 2013 Dec;2(4):323-33
pubmed: 24338291
J Am Coll Cardiol. 2002 May 1;39(9):1518-23
pubmed: 11985917
Can J Cardiol. 2004 Mar 1;20(3):305-9
pubmed: 15054509
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
Am Heart J. 2010 Jun;159(6):933-6
pubmed: 20569702
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
JAMA. 2011 Feb 9;305(6):585-91
pubmed: 21304084
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Heart Lung. 2002 Jul-Aug;31(4):262-70
pubmed: 12122390
Eur Heart J. 2005 Mar;26(6):607-16
pubmed: 15618026
Nephron. 1976;16(1):31-41
pubmed: 1244564
Clin Biochem. 2018 May;55:49-55
pubmed: 29524431
Eur Heart J. 2017 Aug 14;38(31):2392-2407
pubmed: 28821170
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Eur Heart J. 2009 Jul;30(13):1574-83
pubmed: 19406870
Circulation. 2021 Feb 23;143(8):790-804
pubmed: 33267610
JACC Cardiovasc Interv. 2017 Aug 14;10(15):1498-1507
pubmed: 28797425
J Am Heart Assoc. 2018 Feb 27;7(5):
pubmed: 29487111
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
J Am Coll Cardiol. 2020 Oct 6;76(14):1609-1621
pubmed: 33004126
Eur J Cardiothorac Surg. 2020 Jan 1;57(1):168-175
pubmed: 31180497